This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ carisoprodol,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Muscle Relaxation: Carisoprodol acts centrally on the nervous system to produce muscle relaxation by blocking pain sensations between the nerves and the brain. It is commonly prescribed for the short-term relief of muscle spasms, stiffness, and tension associated with conditions such as muscle strains, sprains, and other musculoskeletal injuries.

  2. Acute Pain Management: In addition to its muscle relaxant properties, carisoprodol may provide some degree of pain relief for individuals experiencing acute musculoskeletal pain. By reducing muscle tension and spasm, it can help alleviate associated discomfort and improve mobility.

  3. Adjunctive Therapy: Carisoprodol is often used as an adjunctive therapy along with rest, physical therapy, and other measures to promote recovery from acute musculoskeletal conditions. It is typically prescribed for short-term use (up to two to three weeks) to address acute symptoms during the initial phase of treatment.

  4. Sedation: Carisoprodol can cause sedation and drowsiness as a side effect, which may be beneficial for individuals experiencing muscle spasms or tension-related insomnia. However, this sedative effect can impair cognitive and motor function, so caution is advised when operating machinery or driving while taking carisoprodol.

  5. Anxiolytic Properties: Some individuals may experience mild anxiolytic (anxiety-reducing) effects with carisoprodol due to its sedative properties. However, it is not typically prescribed for the primary treatment of anxiety disorders.

  6. Off-Label Uses: While carisoprodol is primarily indicated for muscle relaxation and pain relief in acute musculoskeletal conditions, it may be used off-label for other conditions, such as fibromyalgia or certain types of chronic pain. However, evidence supporting its efficacy for these purposes is limited, and its use for off-label indications should be carefully considered by healthcare providers.

  7. Dependence and Abuse Potential: Carisoprodol has the potential for abuse and dependence, particularly when used for prolonged periods or at high doses. It is classified as a Schedule IV controlled substance in the United States due to its risk of misuse and addiction. Individuals with a history of substance abuse or dependence should use carisoprodol with caution and under close medical supervision.

  8. Withdrawal Symptoms: Abrupt discontinuation of carisoprodol after prolonged use may lead to withdrawal symptoms, including rebound muscle spasms, insomnia, anxiety, and tremors. Tapering off the medication gradually under medical supervision can help minimize withdrawal effects.

  9. Side Effects: Common side effects of carisoprodol include drowsiness, dizziness, headache, and gastrointestinal upset (such as nausea or vomiting). Less common but more severe side effects may include allergic reactions, skin rash, and paradoxical reactions (such as increased agitation or irritability).

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of carisoprodol,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium breve Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by carisoprodol,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Collinsella genus Decreases
0 1 Streptococcus genus Decreases
0 1 Enterocloster genus Decreases
0 1 Agathobacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Bifidobacterium genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Blautia genus Decreases
0 1 Roseburia genus Decreases
0 1 Clostridioides genus Decreases
0 1 Coprococcus genus Decreases
0 1 Escherichia genus Decreases
0 1 Veillonella genus Decreases
0 1 Odoribacter genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Dorea genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Escherichia coli O1:K1:H7 no rank Decreases
0 1 Escherichia coli O139:H1 no rank Decreases
0 1 Escherichia coli O141:H4 no rank Decreases
0 1 Escherichia coli O145:H34 no rank Decreases
0 1 Escherichia coli O15:H12 no rank Decreases
0 1 Escherichia coli O155:H21 no rank Decreases
0 1 Escherichia coli O158:H23 no rank Decreases
0 1 Escherichia coli O16:H48 no rank Decreases
0 1 Escherichia coli O170:H18 no rank Decreases
0 1 Escherichia coli O18ac:H14 no rank Decreases
0 1 Escherichia coli O19:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H4 no rank Decreases
0 1 Escherichia coli O2:K1:H5 no rank Decreases
0 1 Escherichia coli O2:K1:H7 no rank Decreases
0 1 Escherichia coli O20:H12 no rank Decreases
0 1 Escherichia coli O25:H16 no rank Decreases
0 1 Escherichia coli O55:H7 no rank Decreases
0 1 Escherichia coli O68:H12 no rank Decreases
0 1 Escherichia coli O7:H15 no rank Decreases
0 1 Escherichia coli O78:H51 no rank Decreases
0 1 Escherichia coli O80:H26 no rank Decreases
0 1 Escherichia coli O84:H7 no rank Decreases
0 1 Escherichia coli O85:H1 no rank Decreases
0 1 Escherichia coli O103 serogroup Decreases
0 1 Escherichia coli O111 serogroup Decreases
0 1 Escherichia coli O119 serogroup Decreases
0 1 Escherichia coli O121 serogroup Decreases
0 1 Escherichia coli O145 serogroup Decreases
0 1 Escherichia coli O155 serogroup Decreases
0 1 Escherichia coli O157 serogroup Decreases
0 1 Escherichia coli O177 serogroup Decreases
0 1 Escherichia coli O26 serogroup Decreases
0 1 Escherichia coli O3 serogroup Decreases
0 1 Escherichia coli O43 serogroup Decreases
0 1 Escherichia coli O5 serogroup Decreases
0 1 Escherichia coli O78 serogroup Decreases
0 1 Escherichia coli O86 serogroup Decreases
0 1 Escherichia coli O91 serogroup Decreases
0 1 Escherichia coli H20 serotype Decreases
0 1 Escherichia coli O1:H42 serotype Decreases
0 1 Escherichia coli O1:HNT serotype Decreases
0 1 Escherichia coli O10:H32 serotype Decreases
0 1 Escherichia coli O10:K5(L):H4 serotype Decreases
0 1 Escherichia coli O100:H21 serotype Decreases
0 1 Escherichia coli O103:H11 serotype Decreases
0 1 Escherichia coli O103:H2 serotype Decreases
0 1 Escherichia coli O103:H25 serotype Decreases
0 1 Escherichia coli O104:H21 serotype Decreases
0 1 Escherichia coli O104:H4 serotype Decreases
0 1 Escherichia coli O111:H- serotype Decreases
0 1 Escherichia coli O111:H11 serotype Decreases
0 1 Escherichia coli O111:H8 serotype Decreases
0 1 Escherichia coli O111:NM serotype Decreases
0 1 Escherichia coli O112ab:H8 serotype Decreases
0 1 Escherichia coli O112ac:H19 serotype Decreases
0 1 Escherichia coli O113:H21 serotype Decreases
0 1 Escherichia coli O114:H49 serotype Decreases
0 1 Escherichia coli O118:H16 serotype Decreases
0 1 Escherichia coli O121:H19 serotype Decreases
0 1 Escherichia coli O121:H7 serotype Decreases
0 1 Escherichia coli O123:H11 serotype Decreases
0 1 Escherichia coli O125ac:K+:H10 serotype Decreases
0 1 Escherichia coli O126:H45 serotype Decreases
0 1 Escherichia coli O127:H27 serotype Decreases
0 1 Escherichia coli O127:H6 serotype Decreases
0 1 Escherichia coli O128:H2 serotype Decreases
0 1 Escherichia coli O128ac:H12 serotype Decreases
0 1 Escherichia coli O139:H28 serotype Decreases
0 1 Escherichia coli O145:H25 serotype Decreases
0 1 Escherichia coli O145:H28 serotype Decreases
0 1 Escherichia coli O145:NM serotype Decreases
0 1 Escherichia coli O146:H21 serotype Decreases
0 1 Escherichia coli O15:H18 serotype Decreases
0 1 Escherichia coli O150:H6 serotype Decreases
0 1 Escherichia coli O152:H23 serotype Decreases
0 1 Escherichia coli O153:H2 serotype Decreases
0 1 Escherichia coli O156:H25 serotype Decreases
0 1 Escherichia coli O157:H- serotype Decreases
0 1 Escherichia coli O157:H43 serotype Decreases
0 1 Escherichia coli O157:H7 serotype Decreases
0 1 Escherichia coli O157:NM serotype Decreases
0 1 Escherichia coli O16:H6 serotype Decreases
0 1 Escherichia coli O165:H25 serotype Decreases
0 1 Escherichia coli O167:H26 serotype Decreases
0 1 Escherichia coli O174:H2 serotype Decreases
0 1 Escherichia coli O174:H21 serotype Decreases
0 1 Escherichia coli O174:H8 serotype Decreases
0 1 Escherichia coli O176:H45 serotype Decreases
0 1 Escherichia coli O177:NM serotype Decreases
0 1 Escherichia coli O2:H6 serotype Decreases
0 1 Escherichia coli O2:K2:H1 serotype Decreases
0 1 Escherichia coli O25:H1 serotype Decreases
0 1 Escherichia coli O25:NM serotype Decreases
0 1 Escherichia coli O26:H1 serotype Decreases
0 1 Escherichia coli O26:H11 serotype Decreases
0 1 Escherichia coli O28ac:NM serotype Decreases
0 1 Escherichia coli O29:H4 serotype Decreases
0 1 Escherichia coli O32:H37 serotype Decreases
0 1 Escherichia coli O39:NM serotype Decreases
0 1 Escherichia coli O44:H18 serotype Decreases
0 1 Escherichia coli O45:H2 serotype Decreases
0 1 Escherichia coli O6:H16 serotype Decreases
0 1 Escherichia coli O6:H16:CFA/II serotype Decreases
0 1 Escherichia coli O6:K2:H1 serotype Decreases
0 1 Escherichia coli O69:H11 serotype Decreases
0 1 Escherichia coli O7:H4 serotype Decreases
0 1 Escherichia coli O7:K1 serotype Decreases
0 1 Escherichia coli O78:H12 serotype Decreases
0 1 Escherichia coli O78:H4 serotype Decreases
0 1 Escherichia coli O79:H7 serotype Decreases
0 1 Escherichia coli O8:H8 serotype Decreases
0 1 Escherichia coli O81:NM serotype Decreases
0 1 Escherichia coli O83:H1 serotype Decreases
0 1 Escherichia coli O86:H34 serotype Decreases
0 1 Escherichia coli O89m:H10 serotype Decreases
0 1 Escherichia coli O89m:H9 serotype Decreases
0 1 Escherichia coli O9:H10 serotype Decreases
0 1 Escherichia coli O91:H14 serotype Decreases
0 1 Escherichia coli O91:NM serotype Decreases
0 1 Escherichia coli O99:H6 serotype Decreases
0 1 Escherichia coli ONT:H33 serotype Decreases
1 0 Collinsella aerofaciens species Decreases
1 0 Bifidobacterium longum species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Bacteroides caccae species Decreases
1 0 Streptococcus salivarius species Decreases
0 1 Streptococcus sp. FDAARGOS_192 species Decreases
1 0 Enterocloster bolteae species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Blautia obeum species Decreases
1 0 Roseburia hominis species Decreases
1 0 Bacteroides ovatus species Decreases
1 0 Clostridioides difficile species Decreases
1 0 Coprococcus comes species Decreases
0 1 Bifidobacterium breve species Decreases
0 1 Streptococcus vestibularis species Decreases
0 1 Streptococcus parasanguinis species Decreases
1 0 Escherichia coli species Decreases
0 1 Parolsenella massiliensis species Decreases
0 1 Streptococcus sp. LPB0220 species Decreases
0 1 Streptococcus sp. HSISM1 species Decreases
1 0 Veillonella parvula species Decreases
1 0 Odoribacter splanchnicus species Decreases
0 1 Collinsella stercoris species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
0 1 Parolsenella catena species Decreases
0 1 Bacteroides luhongzhouii species Decreases
0 1 Streptococcus sp. oral taxon 061 species Decreases
1 0 Bifidobacterium adolescentis species Decreases
0 1 Parafannyhessea umbonata species Decreases
0 1 Streptococcus australis species Decreases
0 1 Flavonifractor plautii species Decreases
0 1 Streptococcus lactarius species Decreases
0 1 Bacteroides sp. DH3716P species Decreases
0 1 Streptococcus oralis species Decreases
0 1 Streptococcus sp. Marseille-Q6470 species Decreases
0 1 Streptococcus sp. oral taxon 431 species Decreases
0 1 Bacteroides sp. D2 species Decreases
0 1 Streptococcus infantis species Decreases
0 1 Bacteroides faecium species Decreases
1 0 Bacteroides thetaiotaomicron species Decreases
0 1 Shigella dysenteriae species Decreases
1 0 [Ruminococcus] torques species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Lacrimispora saccharolytica species Decreases
1 0 Mediterraneibacter gnavus species Decreases
0 1 Bifidobacterium longum subsp. infantis subspecies Decreases
0 1 Bifidobacterium longum subsp. longum subspecies Decreases
0 1 Bifidobacterium longum subsp. suillum subspecies Decreases
0 1 Bifidobacterium longum subsp. suis subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of carisoprodol,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0.2 -0.2
ADHD 2.1 0.1 20
Age-Related Macular Degeneration and Glaucoma 0.2 0 0
Allergic Rhinitis (Hay Fever) 1.1 1.7 -0.55
Allergies 2.8 0.5 4.6
Allergy to milk products 0.9 0.5 0.8
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 1.4 3.1 -1.21
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.2 1.5
Ankylosing spondylitis 1.8 0.3 5
Anorexia Nervosa 0.7 1.1 -0.57
Antiphospholipid syndrome (APS) 0.6 0.6
Asthma 2.6 1.1 1.36
Atherosclerosis 1 0.3 2.33
Atrial fibrillation 1.4 1 0.4
Autism 2.7 3 -0.11
Autoimmune Disease 0.6 0.3 1
Barrett esophagus cancer 0.1 0.3 -2
benign prostatic hyperplasia 0.1 0.2 -1
Biofilm 0.8 0.8
Bipolar Disorder 0.3 0.4 -0.33
Brain Trauma 0.8 0.6 0.33
Breast Cancer 0.2 0.2
Cancer (General) 0.2 1.8 -8
Carcinoma 1.4 1.1 0.27
Celiac Disease 1.1 1.5 -0.36
Cerebral Palsy 0.8 0.5 0.6
Chronic Fatigue Syndrome 2.2 2.3 -0.05
Chronic Kidney Disease 1.8 1.1 0.64
Chronic Lyme 0.3 0.4 -0.33
Chronic Obstructive Pulmonary Disease (COPD) 1.7 0.7 1.43
Chronic Urticaria (Hives) 0.7 0.7
Coagulation / Micro clot triggering bacteria 0.6 0.6 0
Cognitive Function 1.1 0.7 0.57
Colorectal Cancer 2.2 1.3 0.69
Constipation 0.3 0.3 0
Coronary artery disease 1.2 1.3 -0.08
COVID-19 4.1 4.8 -0.17
Crohn's Disease 2.1 1.8 0.17
Cushing's Syndrome (hypercortisolism) 0.2 -0.2
cystic fibrosis 0.3 0.9 -2
d-lactic acidosis (one form of brain fog) 0.2 0.2
deep vein thrombosis 0.4 0.7 -0.75
Denture Wearers Oral Shifts 1 1
Depression 4.4 4.7 -0.07
Dermatomyositis 0.3 0.2 0.5
Eczema 0.5 1.2 -1.4
Endometriosis 1.3 0.7 0.86
Eosinophilic Esophagitis 0.4 -0.4
Epilepsy 1.5 0.6 1.5
erectile dysfunction 0.3 0.2 0.5
Fibromyalgia 1 0.7 0.43
Functional constipation / chronic idiopathic constipation 2.2 1.5 0.47
gallstone disease (gsd) 0.7 0.3 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 0.6 -5
Generalized anxiety disorder 1.1 1.5 -0.36
Glioblastoma 0.3 -0.3
Gout 1.7 0.1 16
Graves' disease 0.9 1.5 -0.67
Gulf War Syndrome 0.6 0.3 1
Halitosis 0.6 0.3 1
Hashimoto's thyroiditis 0.9 0.5 0.8
Heart Failure 1.3 1 0.3
hemorrhagic stroke 0.1 0.1
Hidradenitis Suppurativa 0.5 0.1 4
High Histamine/low DAO 0.4 0.2 1
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 1.1 0.6 0.83
Hyperlipidemia (High Blood Fats) 0.5 0.3 0.67
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 1.4 2.4 -0.71
Hypothyroidism 0.5 -0.5
Hypoxia 0.5 0.5
IgA nephropathy (IgAN) 0.5 1.1 -1.2
Inflammatory Bowel Disease 3.3 4 -0.21
Insomnia 1.5 1.1 0.36
Intelligence 0.5 0.5
Intracranial aneurysms 0.4 0.5 -0.25
Irritable Bowel Syndrome 3.1 1.7 0.82
ischemic stroke 1.8 0.7 1.57
Liver Cirrhosis 3 1.3 1.31
Long COVID 3.6 3.5 0.03
Low bone mineral density 0.3 -0.3
Lung Cancer 0.7 0.2 2.5
Lymphoma 0.1 0.1
Mast Cell Issues / mastitis 0.4 0.3 0.33
ME/CFS with IBS 0.7 1 -0.43
ME/CFS without IBS 0.3 0.6 -1
membranous nephropathy 0.3 0.3
Menopause 1.4 0.2 6
Metabolic Syndrome 3.3 2.7 0.22
Mood Disorders 4.4 4.4 0
multiple chemical sensitivity [MCS] 0.9 0.2 3.5
Multiple Sclerosis 2.9 1.7 0.71
Multiple system atrophy (MSA) 0.5 0.4 0.25
myasthenia gravis 0.4 0.2 1
neuropathic pain 1.1 -1.1
Neuropathy (all types) 0.4 0.5 -0.25
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.2 2.5 -0.14
NonCeliac Gluten Sensitivity 0.9 0.4 1.25
Obesity 4.4 2.8 0.57
obsessive-compulsive disorder 1.8 1.4 0.29
Osteoarthritis 1.1 0.7 0.57
Osteoporosis 0.6 0.9 -0.5
pancreatic cancer 0.4 0.3 0.33
Parkinson's Disease 3.6 2.4 0.5
Polycystic ovary syndrome 1.7 1.1 0.55
Postural orthostatic tachycardia syndrome 0.3 -0.3
Premenstrual dysphoric disorder 0.7 0 0
primary biliary cholangitis 0.4 0.6 -0.5
Primary sclerosing cholangitis 1 0.7 0.43
Psoriasis 1.7 1 0.7
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.1 1.8 0.72
Rosacea 0.4 0.2 1
Schizophrenia 2.7 1 1.7
scoliosis 0.3 0.3
Sjögren syndrome 0.9 1 -0.11
Sleep Apnea 0.5 0.6 -0.2
Slow gastric motility / Gastroparesis 0.5 0.2 1.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.7 0.29
Stress / posttraumatic stress disorder 0.8 1.1 -0.38
Systemic Lupus Erythematosus 1.1 0.6 0.83
Tic Disorder 0.4 0.6 -0.5
Tourette syndrome 0.3 0.2 0.5
Type 1 Diabetes 1.3 1.9 -0.46
Type 2 Diabetes 3.9 2 0.95
Ulcerative colitis 1.7 1.8 -0.06
Unhealthy Ageing 1.6 1.1 0.45
Vitiligo 0.7 0.5 0.4

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]